Joanna Kaplanis's Avatar

Joanna Kaplanis

@queenjobo

Genomic Data Scientist @GenomicsEngland

103
Followers
160
Following
8
Posts
18.11.2024
Joined
Posts Following

Latest posts by Joanna Kaplanis @queenjobo

Thank you to all the co-authors who contributed to this work, especially Prasanth Sivakumar, Dasha Deen, and Dalia Kasperaviciute (who aren't on BlueSky), and a big thank you to the participants and families whose data made this study possible!

14.03.2025 10:00 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 0 ๐Ÿ“Œ 0

This work highlights the importance of evaluating each gene prior to inclusion in genomic screening and how understanding the proportion of samples with prioritised variants is crucial for service design

14.03.2025 10:00 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

Our approach prioritised variants in ~80% of participants from the 100,000 Genomes Project and NHS Genomic Medicine Service with diagnostic variants in genes included in the Generation Study.

14.03.2025 10:00 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

Assessing validity of automated variant prioritisation on a gene level led to changes in rules used in variant prioritisation and conditions included.

14.03.2025 10:00 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

Genomic sequencing offers the opportunity to screen for hundreds of rare conditions with a single test. We describe the automated variant prioritisation approach for the Generation Study, which is evaluating genomic newborn screening in 100,000 babies across England.

14.03.2025 10:00 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0
Preview
Assessment of the variant prioritisation strategy for genomic newborn screening in the Generation Study Purpose Genomic sequencing offers the opportunity to screen for hundreds of rare genetic conditions with a single test. To minimise potential negative impact on families and clinical services, it is c...

Our preprint describing and assessing the variant prioritisation approach for genomic newborn screening in the Generation Study @genomicsengland.bsky.social is now on medRxiv www.medrxiv.org/content/10.1...

14.03.2025 10:00 ๐Ÿ‘ 5 ๐Ÿ” 2 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0

We estimate that 3โ€“5% of samples will have prioritised variants requiring manual review by clinical scientists, and that <1% will be taken forward for orthogonal testing and genetic confirmation.

14.03.2025 10:00 ๐Ÿ‘ 0 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0
Preview
Cohort-level analysis of human de novo mutations points to drivers of clonal expansion in spermatogonia In renewing tissues, mutations conferring selective advantage may result in clonal expansions. In contrast to somatic tissues, mutations driving clonal expansions in spermatogonia (CES) are also trans...

Excited to share our preprint: Cohort-level analysis of human de novo mutations points to drivers of clonal expansion in spermatogonia!

We developed methods to uncover drivers of clonal expansions in sperm (CES) using 55k disease trios & gnomAD SNV data. www.medrxiv.org/content/10.1...

06.01.2025 01:06 ๐Ÿ‘ 14 ๐Ÿ” 8 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 1

Impressive work on contribution of common variation to NDD. Not a trivial thing to untangle and really useful FAQ/lay summary. Congrats @qinqinhuang.bsky.social @emiliewigdor.bsky.social @hilarycmartin.bsky.social

21.11.2024 09:21 ๐Ÿ‘ 5 ๐Ÿ” 0 ๐Ÿ’ฌ 1 ๐Ÿ“Œ 0